[go: up one dir, main page]

NO20064874L - Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme - Google Patents

Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme

Info

Publication number
NO20064874L
NO20064874L NO20064874A NO20064874A NO20064874L NO 20064874 L NO20064874 L NO 20064874L NO 20064874 A NO20064874 A NO 20064874A NO 20064874 A NO20064874 A NO 20064874A NO 20064874 L NO20064874 L NO 20064874L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
release pharmaceutical
controlled release
preparation
same
Prior art date
Application number
NO20064874A
Other languages
English (en)
Norwegian (no)
Inventor
Takashi Yoshitake
Mitsuru Mizuno
Kenji Moroshima
Shigeru Aoki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20064874L publication Critical patent/NO20064874L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO20064874A 2004-03-26 2006-10-26 Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme NO20064874L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004093506 2004-03-26
PCT/JP2005/005217 WO2005092336A1 (fr) 2004-03-26 2005-03-23 Préparation de lessivage maîtrisé et procédé de fabrication de ladite préparation

Publications (1)

Publication Number Publication Date
NO20064874L true NO20064874L (no) 2006-12-19

Family

ID=35055974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064874A NO20064874L (no) 2004-03-26 2006-10-26 Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme

Country Status (17)

Country Link
US (2) US20080095839A1 (fr)
EP (1) EP1728512A1 (fr)
JP (1) JPWO2005092336A1 (fr)
KR (1) KR100794078B1 (fr)
CN (1) CN1938026A (fr)
AU (1) AU2005225283B2 (fr)
BR (1) BRPI0509135A (fr)
CA (1) CA2557791C (fr)
IL (1) IL177087A (fr)
MX (1) MXPA06010785A (fr)
MY (1) MY139427A (fr)
NO (1) NO20064874L (fr)
NZ (1) NZ549838A (fr)
RU (1) RU2337687C2 (fr)
TW (1) TW200602085A (fr)
WO (1) WO2005092336A1 (fr)
ZA (1) ZA200607603B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
AU2005225283B2 (en) * 2004-03-26 2008-09-18 Eisai R&D Management Co., Ltd. Controlled-release pharmaceutical composition and method for producing the same
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
EP1930030A1 (fr) * 2005-09-29 2008-06-11 Eisai R&D Management Co., Ltd. Préparation pour impulsion ayant de meilleures propriétés de désintégration in vivo
EP1872778A1 (fr) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Préparation pharmaceutique stable contenant du rabéprazole sodique
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
WO2008015530A2 (fr) * 2006-08-03 2008-02-07 Aurobindo Pharma Limited Formulation orale solide stable d'un medicament acide labile
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
JP2009191036A (ja) * 2008-02-15 2009-08-27 Ss Pharmaceut Co Ltd 時限放出製剤
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
JP2009191034A (ja) * 2008-02-15 2009-08-27 Ss Pharmaceut Co Ltd 時限放出製剤
EP2255794A1 (fr) * 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Enrobage entérique
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法
US20120093904A1 (en) * 2009-07-30 2012-04-19 Evonik Roehm Gmbh Composition comprising an anionic polymeric material and the salt of a saturated monocarboxylic acid having 6 to 22 carbon atoms
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
JP2014122328A (ja) * 2012-11-22 2014-07-03 Shin Etsu Chem Co Ltd 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法
WO2014146093A2 (fr) * 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Compositions anti-abus et méthodes d'utilisation
CN103976972B (zh) * 2014-05-26 2017-09-12 中国药科大学 酒石酸唑吡坦口服脉冲控释给药系统及其制备方法
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
EP3117824A1 (fr) 2015-07-17 2017-01-18 BE Pharbel Manufacturing Microparticules multicouche à libération de composé pharmaceutiquement actif sous forme posologique liquide
SMT202300083T1 (it) 2015-07-17 2023-05-12 Be Pharbel Mfg Microparticelle multistrato rilascianti composti farmaceuticamente attivi in una forma di dosaggio liquida
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
CN105796532B (zh) * 2016-03-28 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种雷贝拉唑钠缓释胶囊及其制备方法
BR112021006027A2 (pt) * 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
KR102810679B1 (ko) * 2019-12-06 2025-05-20 진양제약주식회사 제약 조성물
HUE066609T2 (hu) * 2019-12-11 2024-08-28 Evonik Operations Gmbh Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN113069428B (zh) * 2021-04-02 2023-02-10 珠海润都制药股份有限公司 一种雷贝拉唑钠肠溶片的制备方法
KR102647279B1 (ko) 2021-04-08 2024-03-18 대한뉴팜(주) 라베프라졸의 우수한 방출 특성을 갖는 라베프라졸 나트륨 및 산화마그네슘을 포함하는 제제 및 이의 제조방법
CN119868297A (zh) * 2025-01-21 2025-04-25 东莞市德鸿肠衣有限公司 一种基于天然多糖复合物的可生物降解药用肠衣及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
EP0807433A4 (fr) * 1994-12-27 2005-12-28 Akzo Nobel Nv Preparation a liberation prolongee
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
ES2559766T3 (es) * 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6174902B1 (en) * 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1222922B1 (fr) * 1999-10-20 2007-08-15 Eisai R&D Management Co., Ltd. Procede de stabilisation de composes benzimidazoles
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
CN1589156A (zh) 2001-11-21 2005-03-02 卫材株式会社 含有对酸不稳定的生理活性化合物的制剂组合物及其制法
US20050163836A1 (en) * 2002-04-29 2005-07-28 Pal Fekete Process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose
CA2558535A1 (fr) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique stable comprenant un medicament labile en milieu acide
AU2005225283B2 (en) * 2004-03-26 2008-09-18 Eisai R&D Management Co., Ltd. Controlled-release pharmaceutical composition and method for producing the same
EP1930030A1 (fr) * 2005-09-29 2008-06-11 Eisai R&D Management Co., Ltd. Préparation pour impulsion ayant de meilleures propriétés de désintégration in vivo

Also Published As

Publication number Publication date
CA2557791C (fr) 2011-03-08
CN1938026A (zh) 2007-03-28
RU2006134052A (ru) 2008-04-10
RU2337687C2 (ru) 2008-11-10
CA2557791A1 (fr) 2005-10-06
WO2005092336A1 (fr) 2005-10-06
MY139427A (en) 2009-09-30
IL177087A (en) 2011-11-30
US20080095839A1 (en) 2008-04-24
KR20060134124A (ko) 2006-12-27
MXPA06010785A (es) 2007-03-28
BRPI0509135A (pt) 2007-08-28
NZ549838A (en) 2010-04-30
US20070110806A1 (en) 2007-05-17
ZA200607603B (en) 2007-05-30
IL177087A0 (en) 2006-12-10
AU2005225283B2 (en) 2008-09-18
KR100794078B1 (ko) 2008-01-10
AU2005225283A1 (en) 2005-10-06
TW200602085A (en) 2006-01-16
EP1728512A1 (fr) 2006-12-06
US20120003311A9 (en) 2012-01-05
JPWO2005092336A1 (ja) 2008-02-07

Similar Documents

Publication Publication Date Title
NO20064874L (no) Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme
US6117453A (en) Solid compositions containing polyethylene oxide and an active ingredient
AU2004208606B2 (en) Process for producing coated preparation
CA2348086C (fr) Formulations pharmaceutiques a liberation controlee
RU99126869A (ru) Фармацевтический препарат омепразола
JP4286452B2 (ja) 胃において保護されるオメプラゾール微粒子、その製造方法および医薬製剤
RU2006101082A (ru) Фармацевтическая композиция с набухающим покрытием
JP2006510655A5 (fr)
WO2008085484A3 (fr) Procédé de traitement de l'affection abdominale inflammatoire
AR038157A1 (es) Formas de dosificacion de benzimidazoles sustituidos y su uso
PL356962A1 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
NO20075404L (no) Tablett inneholdende steroidhormoner
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
WO2008000731A2 (fr) Composition pharmaceutique destinée à l'administration par voie orale d'acides gras polyinsaturés oméga et d'au moins un principe actif incompatible avec eux, et procédé de préparation de celle-ci
AU2017304029B2 (en) Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
WO2007054976A3 (fr) Nouvelles compositions pharmaceutiques a liberation controlee a base de lipides
JP2014533656A5 (fr)
WO2004028504A8 (fr) Formes de dosage a liberation modifiee
WO2017018473A1 (fr) Comprimé
JP2019509345A5 (fr)
NO20031409D0 (no) Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse
NO20075715L (no) Depotsammensetning omfattende cefalosporin for behandling av en bakterieinfeksjon
CA2566497A1 (fr) Pastille de methylphenidate multicouche a liberation controlee
NO331643B1 (no) Mikrogranuler som ikke er loselige i magesaft, fremgangsmater for a oppna det samme og farmasoytiske preparater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application